dbACP: A Comprehensive Database of Anti-Cancer Peptides

159 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp01174 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 50% inhibition at 2.5 µg/ml
dbacp01175 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 5 µg/ml
dbacp01176 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 75% inhibition at 10 µg/ml
dbacp01177 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 2.5 µg/ml
dbacp01178 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 42% inhibition at 5 µg/ml
dbacp01179 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 52% inhibition at 10 µg/ml
dbacp01987 Buforin 2 TRSSRAGLQFPVGRVHRLLRK Asiatic toad Disruption of electric potential of the cell membrane; Necrosis, Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer IC50 : 90-95 µg/ml
dbacp02105 Buforin2 TRSSRAGLQFPVGRVHRLLRK Asiatic toad Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 5% Cytotoxicity at 0.5 µg/ml
dbacp02168 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02169 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02170 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02171 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02172 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02173 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >40% at 12.5μM approx.
dbacp02174 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC18 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02175 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02176 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >45% at 12.5μM approx.
dbacp02177 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02178 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC113 Colorectal cancer Cell viability : >80% at 12.5μM approx.
dbacp02179 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02180 C7A KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC107 Colorectal cancer Cell viability : >50% at 12.5μM approx.
dbacp02189 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : 50% at 12.5μM approx.
dbacp02190 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02191 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >50% at 25μM approx..
dbacp02192 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02193 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : 50% at 12.5μM approx.
dbacp02194 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >40% at 12.5μM approx.
dbacp02195 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC18 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02196 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >55% at 12.5μM approx.
dbacp02197 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >80% at 12.5μM approx.
dbacp02198 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >60% at 12.5μM approx.
dbacp02199 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC113 Colorectal cancer Cell viability : >65% at 12.5μM approx.
dbacp02200 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >80% at 12.5μM approx.
dbacp02201 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC107 Colorectal cancer Cell viability : >65% at 12.5μM approx.
dbacp02209 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >50% at 12.5μM approx.
dbacp02210 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >60% at 25μM approx.
dbacp02211 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02212 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >50% at 25μM approx.
dbacp02213 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : 50% at 12.5μM approx.
dbacp02214 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HCT-116 Colorectal cancer Cell viability : >50% at 12.5μM approx.
dbacp02215 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC18 Colorectal cancer Cell viability : >75% at 12.5μM approx.
dbacp02216 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC24 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02217 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC40 Colorectal cancer Cell viability : >85% at 12.5μM approx.
dbacp02218 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC60 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02219 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC113 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02220 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC32 Colorectal cancer Cell viability : >85% at 12.5μM approx.
dbacp02221 C7A-Δ KILRGVAKKIMRTFLRRISKDILTGKK NK-2 peptide based derivatives Apoptosis; Necrosis Cell viability assay HROC107 Colorectal cancer Cell viability : >70% at 12.5μM approx.
dbacp02338 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis MTT/MTS assay SCC12 Skin cancer IC50 : 1 µM
dbacp02339 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis MTT/MTS assay SCC25 Skin cancer IC50 : 2.2 µM
dbacp02340 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis Cell viability assay SCC25 Skin cancer 0.6 ± 0.6% cell growth inhibition at 10 µM
dbacp02341 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis Cell viability assay SCC25 Skin cancer 107.0 ± 5.0% cell growth inhibition at 1 µM
dbacp02466 ChBac3.4 RFRLPFRRPPIRIHPPPFYPPFRRFL Goat Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane TUNEL assay, Reactive oxygen intermediates (ROS) assay A375 cells Melanoma Not found
dbacp02467 ChBac3.4 RFRLPFRRPPIRIHPPPFYPPFRRFL Goat Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane TUNEL assay, Reactive oxygen intermediates (ROS) assay Not specified Pancreatic cancer Not found
dbacp02468 ChBac3.4 RFRLPFRRPPIRIHPPPFYPPFRRFL Goat Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane TUNEL assay, Reactive oxygen intermediates (ROS) assay Not specified Bladder cancer Not found
dbacp02469 ChBac3.4 RFRLPFRRPPIRIHPPPFYPPFRRFL Goat Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane TUNEL assay, Reactive oxygen intermediates (ROS) assay Not specified Breast cancer Not found
dbacp02470 ChBac3.4 RFRLPFRRPPIRIHPPPFYPPFRRFL Goat Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane TUNEL assay, Reactive oxygen intermediates (ROS) assay Not specified Ovarian cancer Not found
dbacp02487 Citropin 1.1 GLFDVIKKVASVIGGL Australian blue mountains tree frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-938 Lymphoma cancer IC50 :40 µg/ml
dbacp02512 Citropin1.1 GLFDVIKKVASVIGGL Australian blue mountains tree frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 60% Cytotoxicity at 0.5 µg/ml
dbacp02513 Citropin1.1 GLFDVIKKVASVIGGL Australian blue mountains tree frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 60% Cytotoxicity at 0.5 µg/ml
dbacp02620 D-K6L9 LKlLKKLlkKLLkLL Not found Necrosis; Membrane disruption Enzyme Immunoassay (EIA) 22RV1 Prostate cancer LC50 : 6 µMol/L
dbacp02621 D-K6L9 LKlLKKLlkKLLkLL Not found Necrosis; Membrane disruption Enzyme Immunoassay (EIA) CL-1 Lung cancer LC50 : 3 µMol/L
dbacp02622 D-K6L9 LKlLKKLlkKLLkLL Not found Necrosis; Membrane disruption Enzyme Immunoassay (EIA) MB-231 Prostate cancer LC50 : 3 µMol/L
dbacp02637 Decoralin SLLSLIRKLI Solitary eumenine wasp Mediate necrosis MTT assay MCF-7 Breast cancer IC50 : 12.5 μmolL−1
dbacp02640 Defensin coprisin MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN Dung beetle Induces apoptosis and necrosis Radial diffusion assay, MIC assay SNU-484 Gastric cancer MIC : ≤ 50 μM
dbacp02641 Defensin coprisin MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN Dung beetle Induces apoptosis and necrosis Radial diffusion assay, MIC assay SNU-601 Gastric cancer MIC : ≤ 50 μM
dbacp02642 Defensin coprisin MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN Dung beetle Induces apoptosis and necrosis Radial diffusion assay, MIC assay SNU-638 Gastric cancer MIC : ≤ 50 μM
dbacp02643 Defensin coprisin MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN Dung beetle Induces apoptosis and necrosis Radial diffusion assay, MIC assay SNU-668 Gastric cancer MIC : ≤ 50 μM
dbacp02646 Demegen P-113 AKRHHGYKRKFH Thrush Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-939 Lymphoma cancer IC50 : 85-90 µg/ml
dbacp02647 Demegen P-113 AKRHHGYKRKFH Amphibian skin peptide Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 15% Cytotoxicity at 0.5 µg/ml
dbacp02914 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 2.5µg/ml
dbacp02915 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 5µg/ml
dbacp02916 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 10µg/ml
dbacp02949 Figainin 2 FLGAILKIGHALAKTVLPMVTNAFKPKQ Skin secretions, Chaco tree frog, South America Cell membrane interaction; Necrosis; Apoptosis MTT/MTS assay B16F10 Murien melanoma IC50 : 12.8 µM
dbacp02950 Figainin 2 FLGAILKIGHALAKTVLPMVTNAFKPKQ Skin secretions, Chaco tree frog, South America Cell membrane interaction; Necrosis; Apoptosis MTT/MTS assay MCF-7 Murien melanoma IC50 : 15.3 µM
dbacp02951 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay B16F10 Skin cancer IC50 : 12.8 µM
dbacp02952 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay B16F10 Breast cancer IC50 : 12.8 µM
dbacp02953 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay MCF-7 Skin cancer IC50 : 15.3 µM
dbacp02954 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 15.3 µM
dbacp03363 Hα-Defensin HNPs-1 NA Not found Cellular necrosis Cell viability assay RCCs, HLA-DRB1*10301 Tumor Inhibition at 12.5 µg/ml
dbacp03364 Hα-Defensin HNPs-2 NA Not found Cellular necrosis Cell viability assay RCCs, HLA-DRB1*10301 Tumor Inhibition at 12.5 µg/ml
dbacp03365 Hα-Defensin HNPs-3 NA Not found Cellular necrosis Cell viability assay RCCs, HLA-DRB1*10301 Tumor Inhibition at 12.5 µg/ml
dbacp03418 Interferon gamma (IFN-gamma) MSYTSYILAFQLCLILGSYGCYCQDTLTRETEHLKAYLKANTSDVANGGPLFLNILRNWKEESDNKIIQSQIVSFYFKLFDNLKDHEVIKKSMESIKEDIFVKFFNSNLTKMDDFQNLTRISVDDRLVQRKAVSELSNVLNFLSPKSNLKKRKRSQTLFRGRRASKY Rabbit Necrosis Not specified Not found Not found Not found
dbacp03419 Interferon gamma (IFN-gamma) MNYTSFILAFQLCAILGSSTYYCQAAFFKEIENLKEYFNASNPDVGDGGPLFLDILKNWKEDSDKKIIQSQIVSFYFKLFENLKDNQVIQKSMDTIKEDLFVKFFNSSTSKLEDFQKLIQIPVNDLKVQRKAISELIKVMNDLSPKANLRKRKRSQNPFRGRRALQ Horse Necrosis; Immunomodulatory activity Not specified Not found Not found Not found
dbacp03473 K4R2-Nal2-S1 Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay PC9 Human lung cancer MIC : 25 μM
dbacp03474 K4R2-Nal2-S1 Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay PC9-G Oral cancer MIC : 25 μM
dbacp03475 K4R2-Nal2-S1 Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay A549 Human lung cancer MIC : 25 μM
dbacp03476 K4R2-Nal2-S1 Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay C9 Oral cancer MIC : 25 μM
dbacp03477 K4R2-Nal2-S1 Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay OECM-1 Human lung cancer MIC : 25 μM
dbacp03478 K4R2-Nal2-S1 Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay SAS Oral cancer MIC : 25 μM
dbacp03479 K6-Nal2-S1 Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay PC9 Human lung cancer MIC : 3.1 μM
dbacp03480 K6-Nal2-S1 Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay PC9-G Oral cancer MIC : 3.1 μM
dbacp03481 K6-Nal2-S1 Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay A549 Human lung cancer MIC : 3.1 μM
dbacp03482 K6-Nal2-S1 Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay C9 Oral cancer MIC : 3.1 μM
dbacp03483 K6-Nal2-S1 Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay OECM-1 Human lung cancer MIC : 3.1 μM
dbacp03484 K6-Nal2-S1 Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay SAS Oral cancer MIC : 3.1 μM
dbacp03600 l3,10,13K7,8K4R2L9 KLlRLLkkLlRLlLK Diastereomeric peptide Plasma membrane perturbation; Necrosis XTT assay B16-F10 Skin cancer LC50 : 2.5 µM
dbacp03601 l3,10,13K7,8K4R2L9 KLlRLLkkLlRLlLK Diastereomeric peptide Plasma membrane perturbation; Necrosis XTT assay D-122 Lung cancer LC50 : 4.5 µM
dbacp03602 l3,4,8,10K5L7 KlllKLKlKlLK Diastereomeric peptide Plasma membrane perturbation; Necrosis XTT assay B16-F10 Skin cancer LC50 : 100 µM
dbacp03603 l3,4,8,10K5L7 KLllKLKlKlLK Diastereomeric peptide Plasma membrane perturbation; Necrosis XTT assay D-122 Lung cancer LC50 : >50 µM
dbacp04302 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay B16F1 Skin cancer IC50 : 13.3 µM
dbacp04303 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay A375 Skin cancer IC50 : 12.7 µM
dbacp04304 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : 15.3 µM
dbacp04308 LTX-328 KAQ-Dip-QKQAW Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : >350 µM
dbacp04652 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Main component of honey bee venom Membrane damage; Apoptotic cell death; Necrosis Cell viability assay SCC25 Skin cancer 102.9 ± 4.1% cell growth inhibition at 1 µM
dbacp04694 MK58911 (a peptide Analog from the mastoparan class of wasps) INWLKIAKKVKGML Greater wax moth Apoptosis; Necrosis Cytotoxicity test MRC5 Not found IC50 : > 500 µg/mL
dbacp04695 MK58911 (a peptide Analog from the mastoparan class of wasps) INWLKIAKKVKGML Greater wax moth Apoptosis; Necrosis Cytotoxicity test U87 Not found IC50 : > 500 µg/mL
dbacp04820 Nal2-S1 Ac-KKWRKWLAKK-NH2 Not found Necrosis; Apoptosis MTT assay PC9 Human Lung cancer MIC : 25 μM
dbacp04821 Nal2-S1 Ac-KKWRKWLAKK-NH2 Not found Necrosis; Apoptosis MTT assay PC9-G Oral cancer MIC : 25 μM
dbacp04822 Nal2-S1 Ac-KKWRKWLAKK-NH2 Not found Necrosis; Apoptosis MTT assay A549 Human Lung cancer MIC : 25 μM
dbacp04823 Nal2-S1 Ac-KKWRKWLAKK-NH2 Not found Necrosis; Apoptosis MTT assay C9 Oral cancer MIC : 25 μM
dbacp04824 Nal2-S1 Ac-KKWRKWLAKK-NH2 Not found Necrosis; Apoptosis MTT assay OECM-1 Human Lung cancer MIC : 25 μM
dbacp04825 Nal2-S1 Ac-KKWRKWLAKK-NH2 Not found Necrosis; Apoptosis MTT assay SAS Oral cancer MIC : 25 μM
dbacp05012 Omiganan MBI-226 ILRWPWWPWRRK Cattle neutrophils Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer IC50 : 80 - 85 µg/ml
dbacp05013 Omiganan MBI-226 ILRWPWWPWRRK Helical peptide with a predominance of one or more amino acids tryptophane-rich Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 27% Cytotoxicity at 0.5 µg/ml
dbacp05038 P18 KWKLFKKIPKFLHLAKKF Bovine lactoferrin (Lf-B) Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 92.2 ± 1.02% cell viability at 10 µM
dbacp05039 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 71.1 ± 2.84% cell viability at 20 µM
dbacp05040 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 50 ± 3.09% cell viability at 40 µM
dbacp05041 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 31.5 ± 1.49% cell viability at 60 µM
dbacp05042 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 13.8 ± 1.44% cell viability at 80 µM
dbacp05043 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 86 ± 0.57% cell viability at 10 µM
dbacp05044 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 63.8 ± 0.8% cell viability at 20 µM
dbacp05045 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 47.5 ± 1.66% cell viability at 40 µM
dbacp05046 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 26.9 ± 0.5% cell viability at 60 µM
dbacp05047 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 6.5 ± 1.07% cell viability at 80 µM
dbacp05467 Peptidoglycan recognition protein 1 MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE Mouse Necrosis; Apoptosis Cytotoxicity assay VMR-0 Mammary adenocarcinoma Not found
dbacp05468 Peptidoglycan recognition protein 1 MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE Mouse Necrosis; Apoptosis Cytotoxicity assay VMR-L Mammary adenocarcinoma Not found
dbacp05469 Peptidoglycan recognition protein 1 MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE Mouse Necrosis; Apoptosis Cytotoxicity assay CSML-0 Mammary adenocarcinoma Not found
dbacp05470 Peptidoglycan recognition protein 1 MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE Mouse Necrosis; Apoptosis Cytotoxicity assay CSML-100 Mammary adenocarcinoma Not found
dbacp05488 Pexiganan MSI-78 GIGKFLKKAKKFGKAFVKILKK Analog of African clawed frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-941 Lymphoma cancer IC50 : 20-30 µg/ml
dbacp05569 Piscidin-4 FIHHIIGGLFSAGKAIHRLIRRRRR Nile tilapia Necrosis Adenosine triphosphate (ATP) assay A549 Non-small cell Lung cancer (NSCLC) IC50 : 1.922 – 27.62 µM
dbacp05570 Piscidin-4 FIHHIIGGLFSAGKAIHRLIRRRRR Nile tilapia Necrosis Adenosine triphosphate (ATP) assay NCI-H661 Non-small cell Lung cancer (NSCLC) IC50 : 3.769 – 14.17 µM
dbacp05571 Piscidin-4 FIHHIIGGLFSAGKAIHRLIRRRRR Nile tilapia Necrosis Adenosine triphosphate (ATP) assay NCI-H1975 Non-small cell Lung cancer (NSCLC) IC50 : 1.241 – 5.472 µM
dbacp05572 Piscidin-4 FIHHIIGGLFSAGKAIHRLIRRRRR Nile tilapia Necrosis Adenosine triphosphate (ATP) assay HCC827 Non-small cell Lung cancer (NSCLC) IC50 :10.61 – 18.52 µM
dbacp05649 Protegrin 1 RGGRLCYCRRRFCVCVGR Alpha helical peptide without cysteines Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-942 Lymphoma cancer IC50 : 30-40 µg/ml
dbacp05697 Psyle A GIACGESCVFLGCFIPGCSCKSKVCYFN **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05698 Psyle A GIACGESCVFLGCFIPGCSCKSKVCYFN **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05699 Psyle A GIACGESCVFLGCFIPGCSCKSKVCYFN **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05700 Psyle C KLCGETCFKFKCYTPGCSCSYPFCK **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05701 Psyle C KLCGETCFKFKCYTPGCSCSYPFCK **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05702 Psyle C KLCGETCFKFKCYTPGCSCSYPFCK **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05703 Psyle E GVIPCGESCVFIPCISSVLGCSCKNKVCYRD **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05704 Psyle E GVIPCGESCVFIPCISSVLGCSCKNKVCYRD **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp05705 Psyle E GVIPCGESCVFIPCISSVLGCSCKNKVCYRD **Eumachia leptothyrsa**, New Guinea, Philippines, Sulawesi Necrosis; Cell membrane rupture Not specified Not found Not found Not found
dbacp06008 S1 (Ac-KKWRKWLAKK-NH2) Ac-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay PC9 Human Lung cancer Not found
dbacp06009 S1 (Ac-KKWRKWLAKK-NH2) Ac-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay PC9-G Oral cancer Not found
dbacp06010 S1 (Ac-KKWRKWLAKK-NH2) Ac-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay A549 Human lung cancer Not found
dbacp06011 S1 (Ac-KKWRKWLAKK-NH2) Ac-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay C9 Oral cancer Not found
dbacp06012 S1 (Ac-KKWRKWLAKK-NH2) Ac-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay OECM-1 Human lung cancer Not found
dbacp06013 S1 (Ac-KKWRKWLAKK-NH2) Ac-NAl-NAl-KKWRKWLAKK-NH2 Not found Necrosis or apoptosis MTT assay SAS Oral cancer Not found
dbacp06226 Temporin A FLPLIGRVLSGIL Common frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-943 Lymphoma cancer IC50 : 80-90 µg/ml
dbacp06324 TP4 FIHHIIGGLFSAGKAIHRLIRRRRR Nile tilapia Necrosis Not specified Not found Brain cancer Not found
dbacp06404 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 49.4% Cytotoxic at 0.1 µg/ml
dbacp06405 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 51.2% Cytotoxic at 1 µg/ml
dbacp06406 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 53.0% Cytotoxic at 10 µg/ml
dbacp06407 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 61.2% Cytotoxic at 100 µg/ml
dbacp06408 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 39.0% Cytotoxic at 0.1 µg/ml
dbacp06409 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 20.8% Cytotoxic at 1 µg/ml
dbacp06410 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 33.8% Cytotoxic at 10 µg/ml
dbacp06411 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 35.6% Cytotoxic at 100 µg/ml